Recurrent pancreatitis is a potentially fatal complication of severe hypertriglyceridemia. Genetic defects and lifestyle risk factors may render this condition unresponsive to current treatments.
We report this first case of long-term management of intractable near-fatal recurrent pancreatitis secondary to severe hypertriglyceridemia by a novel use of lomitapide, an inhibitor of microsomal triglyceride transfer protein, recently approved for treatment of familial homozygous hypercholesterolemia. The patient had been hospitalized many times for pancreatitis since age 15 years. Her serum triglyceride level averaged 3900 mg/dL while she received therapy with approved lipid drugs. She is homozygous for a coding mutation (P234L) in lipoprotein lipase, leaving her unable to metabolize triglycerides in chylomicrons and very low density lipoproteins (VLDL). Lomitapide reduces the secretion of chylomicrons and VLDL. Lomitapide, which was started when she was 44 years old after near-fatal pancreatitis, lowered her fasting triglyceride level from greater than 3000 mg/dL to a mean (SD) of 903 (870) mg/dL while she received 30 mg/d and to 524 (265) mg/dL while she received 40 mg/d; eliminated chronic abdominal pain; and prevented pancreatitis. However, fatty liver, present before treatment, progressed to steatohepatitis and fibrosis after 12 to 13 years.
Conclusions and Relevance
Lomitapide prevented pancreatitis in severe intractable hypertriglyceridemia but at a potential long-term cost of hepatotoxicity.
The dose of lomitapide was adjusted to balance efficacy and tolerability. The patient’s triglyceride level when receiving 12.5 mg/d averaged 2110 mg/dL, when receiving the alternating dose regimen of 12.5 mg/d and 25 mg/d averaged 1416 mg/dL, and when receiving 25 mg/d averaged 371 mg/dL. Discontinued indicates temporary cessation of lomitapide. (To convert triglycerides to millimoles per liter, multiply by 0.0113.)
Each episode of pancreatitis (P) is defined as brief uncomplicated hospitalization associated with not taking the drug or exceptionally high dietary fat intake (The 2 P’s close to each other are simply 2 pancreatitis episodes that occurred at the times indicated on the x-axis). At year 4, a 6-month trial of adding fenofibrate, 200 mg/d, to lomitapide, 12.5 mg/d, to try to control the hypertriglyceridemia on a lower dose of lomitapide was a failure. The patient’s mean serum TG level was 3175 mg/dL (range, 2525-3880 mg/dL; N = 4 TG tests) with the combination, compared with 2345 mg/dL (range, 1041-3600 mg/dL; N = 6 TG measurements) during treatment with lomitapide, 12.5 mg/d. This time period is indicated by vertical gray columns. In the 10th year, lomitapide was reformulated into 20- and 40-mg capsules. The mean (SD) TG levels during treatment with 20 mg/d was 1604 (1030) mg/dL (median, 1331 mg/dL; N = 13 TG measurements); during treatment with the alternating dose of 20 mg/d and 40 mg/d, 903 (870) mg/dL (median, 703 mg/dL; N = 10 TG measurements); and during treatment with the 40-mg/d dose, 524 (265) mg/dL (median, 542 mg/dL; N = 4 TG measurements). B indicates baseline. (To convert TG to millimoles per liter, multiply by 0.0113.)
The upper limits of normal were 40 U/L for ALT (A) and 35 U/L for AST (B). Findings of the liver biopsy described in more detail in the subsection titled “Hepatic Toxicity of Lomitapide.” B indicates baseline. (To convert ALT and AST to microkatals per liter, multiply by 0.0167.)
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.